Kyverna Therapeutics: Promising Outlook with Breakthrough CAR-T Therapy in Autoimmune Diseases

William Blair analyst Sami Corwin maintains a Buy rating on Kyverna Therapeutics (KYTX) due to promising results from the miv-cel (KYV-101) trial in Stiff Person Syndrome, supporting a Biologics License Application. The therapy shows potential as the first FDA-approved CAR-T for autoimmune diseases. Despite stock price increases and regulatory uncertainties, frequent FDA interactions reduce risk. H.C. Wainwright also reiterates a Buy rating with a $20 price target.

Kyverna Therapeutics, Immunome, Almonty Industries And Other Big Stocks Moving Higher On Monday

Kyverna Therapeutics shares surged 31% to $11.49 after announcing positive Phase 2 trial data for miv-cel in stiff person syndrome. Other notable stock gains include Beneficient up 29.3%, Immunome up 25.5% following positive Phase 3 trial results, and Almonty Industries up 9.1% after withdrawing a base shelf prospectus. Additional stocks like Falcon’s Beyond Global, XBP Global Holdings, and others also recorded gains on Monday.

Kyverna Stock Rockets After Cell Therapy Helps Patients Walk Again In Rare Disorder

Kyverna Therapeutics' stock surged 38.15% after announcing positive Phase 2 trial results for its CAR-T therapy, mivocabtagene autoleucel, in treating stiff person syndrome. The therapy showed significant improvements in mobility and reduced disability, with 81% of patients exceeding a 20% improvement in the timed 25-foot walk. The company plans to submit a Biologics License Application to the FDA by 2026. The stock reached a new 52-week high, trading at $12.13.

Kyverna Therapeutics shares are trading higher after the company announced topline data from KYSA-8.

Kyverna shares jump on strong results from SPS clinical trial

Kyverna Therapeutics shares rose 14% after reporting positive results from its Phase 2 KYSA-8 study on mivocabtagene autoleucel for stiff person syndrome, showing significant benefits across all endpoints.